CHAMPIONS ONCOLOGY, INC. Deferred Foreign Income Tax Expense (Benefit)
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Deferred Foreign Income Tax Expense (Benefit) of $11.00 thousand for the 12-month period ending 2016-04-30, per its 10-K filed 2016-07-29.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2016-07-29
- CHAMPIONS ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2016 was $11.00K, a 37.50% increase from fiscal 2015.
- CHAMPIONS ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2015 was $8.00K.
- CHAMPIONS ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2014 was $0.00.
- CHAMPIONS ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2013 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2016-04-30 | $11.00K 10-K · filed 2016-07-29 |
| 2015-04-30 | $8.00K 10-K · filed 2016-07-29 |
| 2014-04-30 | $0.00 10-K · filed 2015-07-29 |
| 2013-04-30 | $0.00 10-K · filed 2014-07-28 |
| 2012-04-30 | -$68.00K 10-K · filed 2013-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |